The R21 vaccine, a variation to RTS,S (that displays a higher ratio of CSP to hepatitis B surface antigen), showed more than 70% protective efficacy against uncomplicated malaria in a phase 2b clinical trial [178]. The gene discussed is DNAJC5; the disease is malaria.